announcement out, page-33

"it all looks pretty good to me. at 2c its valued at about 30m which by comparison to others in the same field is cheap. at 3c its about 45m which still looks attractive"

I agree MattKid a very interesting few years ahead but I still find it very hard to actually use any of the cross field comparisons as it's still not expected to have any candidates in the clinic for well over a year 2H 2014 OR 2015, and I guess for any comparison it is always against companies that have at least one or more already in clinic. I think the best case value I can do from where it is becomes based on simply the value it raises the capital at completes the acquisition and then lists - it's up to market from there.